New York State Common Retirement Fund Sells 92,771 Shares of BioNTech SE (NASDAQ:BNTX)

New York State Common Retirement Fund lessened its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 42.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 125,296 shares of the company’s stock after selling 92,771 shares during the period. New York State Common Retirement Fund’s holdings in BioNTech were worth $14,277,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Baillie Gifford & Co. lifted its stake in shares of BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after buying an additional 31,773 shares in the last quarter. FMR LLC raised its holdings in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after acquiring an additional 5,598,190 shares during the period. Fred Alger Management LLC purchased a new stake in shares of BioNTech during the third quarter worth $59,485,000. DekaBank Deutsche Girozentrale boosted its holdings in shares of BioNTech by 12.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock worth $56,886,000 after acquiring an additional 53,800 shares during the period. Finally, abrdn plc raised its stake in shares of BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company’s stock valued at $43,947,000 after purchasing an additional 159,676 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of BioNTech stock opened at $120.01 on Monday. The firm has a market capitalization of $28.77 billion, a PE ratio of -57.15 and a beta of 0.17. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The business’s 50-day moving average price is $117.26 and its 200-day moving average price is $111.03.

Analyst Upgrades and Downgrades

Several brokerages have commented on BNTX. HC Wainwright restated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Truist Financial assumed coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the company from $90.00 to $137.00 in a report on Friday, November 8th. Finally, Berenberg Bank started coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.